Eugene Shenderov, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses a Phase II trial (NCT02923180) of the novel anti-B7-H3 monoclonal antibody enoblituzumab as a neoadjuvant treatment for intermediate and high-risk patients with localised prostate cancer. 32 patients, 75% of whom were very high-risk, received 6 weeks of treatment with enoblituzumab, prior to prostatectomy. There was then a follow-up of up to 3 years. The primary endpoints of the study were safety and preliminary efficacy, which was assessed based on PSA non-recurrence one year post-prostatectomy. In terms of safety, the treatment was well-tolerated by most patients, with 4 patients experiencing treatable adverse events of grade 3 or higher. 66% of patients had no recurrence of PSA one-year post-prostatectomy. Some patients experienced a reduction in PSA during neoadjuvant treatment, and further research is on-going as to the biological mechanisms behind this. There were also significant immune-infiltrate differences observed from biopsy to prostatectomy. Dr Shenderov emphasises the preliminary stage of this research and discusses the next steps for investigating this treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.